v3 Template
P

Perspective Therapeutics Inc.

Radiopharmaceuticals / Biotechnology Seattle, WA, United States ~520 employees
Founded
--
Employees (Est.)
~520
26 leaders known
Total Funding
$513.0M
Funding Rounds
5
Last Funding
2026-02-02

About Perspective Therapeutics Inc.

Perspective Therapeutics is a radiopharmaceutical company focused on transforming cancer treatment through targeted alpha particle therapy (TAT). Their mission is to develop image-guided therapies that deliver powerful radiation directly to cancer cells, minimizing damage to healthy tissue and improving patient outcomes.

Products & Services

Pb-based α-Particle Therapy:A revolutionary therapy using Pb-212 to deliver potent alpha radiation directly to cancer cells via high-affinity targeting peptides.
Precision Radiopharmaceuticals:Advanced radiopharmaceuticals designed for precise targeting of tumor cells with minimal off-target effects.
Pb-Specific Chelator (PSC):A proprietary chelator used to conjugate radioisotopes to targeting peptides for effective cancer therapy.
Theranostics Platform:An image-guided platform that confirms tumor target expression before treatment to optimize patient selection and outcomes.
VMT-α-NET:A candidate for neuroendocrine tumors and other SSTR2-expressing tumors, currently in clinical evaluation.
VMT01/02:Therapy and imaging for melanoma targeting MC1R, with ongoing trials as monotherapy and in combination with nivolumab.
PSV359:A therapy targeting FAP-α for multiple solid tumors, currently enrolling patients in Phase 1/2a studies.
Pre-Targeting Platform:An innovative platform under evaluation for multiple solid tumors.

Specialties

Targeted Alpha Particle Therapy Image-Guided Theranostics Radiopharmaceutical Development Cancer Treatment Pb-212 Based Therapies

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Underwritten Offering
T: -
FT: Underwritten Offering
A: 175000000
MR: -
FA: $175 million
FAN: 175000000
D: 2026-02-02
FD: 2026-02-02
8 investors
2 RT: Underwritten Offering
T: -
FT: Underwritten Offering
A: 80000000
MR: -
FA: approximately $80 million
FAN: 80000000
D: 2024-05-24
FD: 2024-05-24
4 investors
3 RT: Private Placement
T: -
FT: Private Placement
A: 87400000
MR: -
FA: 87.4 million
FAN: 87400000
D: 2024-03-04
FD: 2024-03-04
1 investors
4 RT: Public Offering and Private Placement
T: -
FT: Public Offering and Private Placement
A: 89800000
MR: -
FA: $89.8 million
FAN: 89800000
D: 2024-01-22
FD: 2024-01-22
3 investors
5 RT: Public Offering and Private Placement
T: -
FT: Public Offering and Private Placement
A: 80800000
MR: -
FA: $80.8 million
FAN: 80800000
D: 2024-01-18
FD: 2024-01-18
2 investors
Underwritten Offering Latest
2026-02-02
$175.0M
8 investors (Pro only)
Underwritten Offering 2024-05-24
$80.0M
Private Placement 2024-03-04
$87.4M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

L

Lori Woods

Chairperson

T

Thijs Spoor

Chief Executive Officer

R

Robert Froman Williamson III

Member of the Board of Directors

F

Frank Morich

Member of the Board of Directors

H

Heidi Henson

Member of the Board of Directors

M

Maya Martinez-Davis

Member of the Board of Directors

View 23 more team members with Pro

Unlock Full Team Directory

Recent News

Perspective Therapeutics Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Radiopharmaceuticals / Biotechnology
Company Size
~520 employees (est.)
Locations
Seattle, WA, United States
Seattle
SEATTLE

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro